Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 201 to 250 of 635 results for diabetes

  1. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.

  2. Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)

    NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .

  3. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  4. Dexcom G6 for real-time continuous glucose monitoring (MIB233)

    NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .

  5. Multimorbidity (QS153)

    This quality standard covers clinical assessment, prioritising and managing healthcare for adults aged 18 years and over with 2 or more long-term health conditions (multimorbidity). At least 1 of these conditions must be a physical health condition. It describes high-quality care in priority areas for improvement.

  6. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    treatment in people with type 1 diabetes? Any explanatory notes(if applicable) People with type 1 diabetes have increased...

  7. Older people with social care needs and multiple long-term conditions (NG22)

    This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

  8. Cardiovascular disease prevention (PH25)

    This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.

  9. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  10. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  11. Familial hypercholesterolaemia: identification and management (CG71)

    This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

  12. What are the roles of insulin pump therapy (continuous subcutaneous insulin infusion) and continuous glucose monitoring in helping women with diabetes to achieve blood glucose targets before pregnancy?

    with diabetes to achieve blood glucose targets before pregnancy? Any explanatory notes(if applicable) Babies born to women with...

  13. What is the most clinically and cost-effective tool for diagnosing peripheral arterial disease in people with diabetes?

    peripheral arterial disease in people with diabetes? Any explanatory notes(if applicable) People with diabetes are at...

  14. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

  15. LY3209590 for treating type 2 diabetes in people on daily insulin injections TS ID 11837

      Status ...

  16. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

  17. The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months

    combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma who are recorded as current...

  18. Self-monitoring of blood glucose levels: What is the optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes?

    optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes? Any explanatory notes(if applicable) Why this is...

  19. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

  20. NICEimpact children and young people's healthcare

    Find out about the progress made by the health and care system in implementing NICE guidance on children and young people's healthcare

  21. Psychosis and schizophrenia in children and young people: recognition and management (CG155)

    This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.

  22. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

  23. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

  24. Physical activity: walking and cycling (PH41)

    This guideline covers encouraging people to increase the amount they walk or cycle for travel or recreation purposes.

  25. Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

    Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

  26. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (DG52)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers

  27. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  28. In women with type 1 diabetes who are already pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring?

    Recommendation ID NG3/7 Question In women with type 1 diabetes who are already pregnant, what is the most effective method of glucose...

  29. Ambulatory Acute Foot Service - Royal Free London NHS FT

    How did you implement the project A bid was submitted to the NHSE Diabetes Transformation Fund to gain funding to establish the AAFS and...

  30. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults (aged 18 and over) and treatment to prevent cardiovascular disease. It describes high-quality care in priority areas for improvement.

  31. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

  32. Patient decision aids

    cancer in the past. Type 2 diabetes: agreeing my blood glucose (HbA1c) target If you have type 2 diabetes you may have...

  33. Dementia: assessment, management and support for people living with dementia and their carers (NG97)

    This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

  34. Effectiveness of SGLT2 inhibitors for different ethnic groups: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across different ethnic groups?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across...

  35. LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections TS ID 11836

      Status ...

  36. Developing an Annual Review Clinic for People with Rheumatoid Arthritis

    investigation / management as appropriate (we picked up 2 new cases of diabetes and we referred 1 patient direct to cardiology for...

  37. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 19 June 2024

  38. Semaglutide for managing overweight and obesity (TA875)

    Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.

  39. Community pharmacies: promoting health and wellbeing (QS196)

    This quality standard covers how community pharmacies can support the health and wellbeing of the local population. It describes high-quality care in priority areas for improvement.

  40. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

  41. Current evidence on the safety and efficacy of implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes is limited in quality and quantity. Therefore the procedure should only be used in the context of research.

    of implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes is limited in quality and quantity. Therefore the...

  42. Empagliflozin with linagliptin for treating type 2 diabetes in people aged 10 to 17 TS ID 11818

      Status ...

  43. Weight management before, during and after pregnancy (PH27)

    This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.

  44. In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring intermittent capillary blood glucose monitoring?

    Recommendation ID NG3/6 Question In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of